Given the pathogenetic role of mutant TP53 in AML, we reason that similar strategies could reduce the phenotypic plasticity and decrease the adaptive potential of AML cells to a broad range of therapeutics. The gene discussed is TP53; the disease is acute myeloid leukemia.